Dengue Clinical Trial - Dengue 3 Human Infection Model (DENV-3)

Status Completed

Clinical Trial Summary

To evaluate the effectiveness of candidate dengue vaccine formulations, it is prudent to develop an appropriate challenge model. This study will examine the safety and effectiveness of the Dengue 3 Live Virus Human Challenge (DENV-3-LVHC) product and assess the ability of this virus strain to elicit an uncomplicated dengue-like illness.

Clinical Trial Description

Healthy subjects between 18 and 45 years old will be inoculated with Dengue 3 Live Virus Human Challenge (DENV-3-LVHC) in a dose ranging study. Subjects will be closely monitored for the first 28 days with continued follow up through 6 months. Clinical and laboratory parameters, viremia and antibody levels will be assessed. The goal is to determine the dose that produces uncomplicated dengue-like illness. ;

Study Design

Related Conditions & MeSH terms

Dengue

Clinical Trial Details

NCT number	NCT04298138
Study type	Interventional
Source	State University of New York - Upstate Medical University
Contact
Status	Completed
Phase	Phase 1
Start date	August 3, 2020
Completion date	December 14, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05321264` - Educational Intervention to Promote Control Behaviors and Prevention of Dengue	N/A
Completed	`NCT01436396` - Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers	Phase 3
Completed	`NCT01391819` - Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children	N/A
Completed	`NCT03641339` - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans	N/A
Completed	`NCT02833584` - Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults	N/A
Completed	`NCT02433652` - Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2	Phase 1
Enrolling by invitation	`NCT02016027` - Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter	Phase 1
Completed	`NCT01477671` - Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children	N/A
Recruiting	`NCT00377754` - Prospective Study of Infant Dengue	N/A
Recruiting	`NCT05919277` - A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
Recruiting	`NCT04582474` - Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso	N/A
Completed	`NCT01983553` - Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Completed	`NCT03803618` - Dengue Effectiveness Study in the Philippines
Active, not recruiting	`NCT05967455` - Homologous Re-infection With Dengue 1 or Dengue 3	Phase 1
Completed	`NCT03631719` - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Recruiting	`NCT02606019` - The Use of Biomarkers in Predicting Dengue Outcome	N/A
Completed	`NCT02372175` - Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain	Phase 1
Active, not recruiting	`NCT01696422` - Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine	Phase 2
Completed	`NCT00993447` - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America	Phase 2
Completed	`NCT00375726` - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults	Phase 1